FIELD: biochemistry.
SUBSTANCE: what is described is an oncolytic virus containing a nucleic acid which encodes a hexosyltransferase enzyme in which the enzyme is an enzyme of alpha 1,3-galactosyl transferase. What is also described is a pharmaceutical composition containing the described oncolytic virus. There are also described methods of treating a neoplasm or cancer patient using said oncolytic virus.
EFFECT: invention enables treating new growths or cancer by specifically lysing tumor cells.
20 cl, 9 dwg, 8 ex
Title | Year | Author | Number |
---|---|---|---|
ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH | 2016 |
|
RU2725799C2 |
APPLICATION OF MYXOMA VIRUS FOR THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRUS INFECTION | 2004 |
|
RU2362584C2 |
MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
CONSTRUCTION OF OBLIGATE VECTOR BASED ON ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) AND CONSTRUCTS FOR CANCER THERAPY | 2016 |
|
RU2751236C2 |
ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS | 2009 |
|
RU2520823C2 |
COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
USE OF COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT | 2006 |
|
RU2461630C2 |
COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2540490C2 |
TREATMENT OF TUMORS WITH A COMBINATION OF ONCOLYTIC ADENOVIRUS AND CDK4/6 INHIBITOR | 2019 |
|
RU2811278C2 |
Authors
Dates
2020-05-15—Published
2016-04-07—Filed